Gold prices steady, holding sharp gains in wake of soft U.S. jobs data
CAMBRIDGE, MA—Eliana Clark, Executive Vice President and Chief Technical Officer of Intellia Therapeutics, Inc. (NASDAQ:NTLA), recently made a notable transaction involving the company’s common stock. On March 4, Clark sold 679 shares at a price of $8.99 each, totaling approximately $6,104. The transaction comes as NTLA trades near its 52-week low of $8.96, with the stock down about 71% over the past year. According to InvestingPro analysis, the stock currently appears undervalued.
The sale was part of a mandatory "sell-to-cover" transaction aimed at fulfilling tax withholding obligations upon the vesting of restricted stock units (RSUs) on March 1. This transaction was not a voluntary trade by Clark. For deeper insights into insider trading patterns and comprehensive analysis, InvestingPro subscribers can access detailed research reports covering over 1,400 US stocks, including NTLA.
In addition to the sale, Clark acquired 32,000 shares of common stock and 45,714 stock options on March 1, both at no cost. The stock options have an exercise price of $10.09 per share and are set to expire on February 28, 2035. Following these transactions, Clark holds 95,369 shares of Intellia’s common stock, representing a stake in the company’s $978 million market capitalization. While the company maintains strong liquidity with a current ratio of 5.77, InvestingPro data indicates the company is quickly burning through cash.
In other recent news, Intellia Therapeutics reported a better-than-expected fourth-quarter performance, with adjusted earnings per share of -$1.27, surpassing analyst estimates of -$1.34. The company’s revenue reached $12.87 million, significantly exceeding the consensus forecast of $9.28 million. Intellia’s cash reserves stood at approximately $861.7 million at the end of 2024, projected to support operations into the first half of 2027. Alongside these financial updates, Intellia has made strides in its clinical pipeline, notably dosing the first patient in the Phase 3 HAELO study for hereditary angioedema (HAE) and planning to complete enrollment by the second half of 2025.
In terms of analyst perspectives, Truist Securities maintained a Buy rating on Intellia but reduced the price target from $90 to $50, citing competitive pressures and a tempered commercial outlook for its ATTR amyloidosis treatment. Goldman Sachs, however, downgraded the stock from Neutral to Sell, setting a price target of $9 due to concerns about the competitive landscape and the commercial viability of Intellia’s gene-editing treatments. Similarly, JPMorgan downgraded Intellia from Overweight to Neutral, lowering the price target to $13, reflecting skepticism about immediate positive catalysts.
Conversely, Citi analysts raised their price target from $12 to $14, maintaining a Neutral rating, following Intellia’s full-year 2024 earnings report. They noted the company’s commitment to clinical stage execution, particularly highlighting the progress in the Phase 3 MAGNITUDE-2 study for transthyretin amyloidosis. Despite mixed analyst opinions, Intellia remains focused on advancing its key programs, including its NTLA-2002 treatment, with plans to submit a Biologics License Application in 2026 for a potential 2027 launch.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.